Clinical Trials

Clinical Trials

VDA-1102 ointment is being developed under an IND from the FDA as a topical treatment for a variety of skin cancers. 

Phase 1a study

A Phase 1a randomized, double-blinded, placebo-controlled, dose-escalation study in healthy older-adult volunteers to evaluate the safety, tolerability, and pharmacokinetics of a single topical dermal application of VDA-1102 ointment was conducted in the US.

There were no safety concerns in this study, and it was concluded that a single dose of the drug was well-tolerated by all subjects enrolled.

Phase 1b study

A Phase 1b randomized, double-blinded, placebo-controlled, dose-escalation study in subjects with actinic keratosis (AK) to evaluate the safety, tolerability, and pharmacokinetics of a multiple topical dermal application of VDA-1102 ointment was conducted in the US.

There were no safety concerns in this study, and it was concluded that multiple daily doses of the drug was well-tolerated by all subjects enrolled.

Phase 2a study in AK

A multi-center Phase 2a randomized, double-blinded, placebo-controlled study in subjects with actinic keratosis (AK) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (efficacy) of VDA-1102 ointment applied topically (dermal) once-daily for 28 days.

This study is currently enrolling, and is expected to conclude in the first half of 2017.